BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
TargeGen announces initiation of clinical trial of JAK2 inhibitor TG101348 in myeloproliferative disease patients
News | 01. 31. 2008
TargeGen
TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.
